Close

What are ADC's

Our services

ADC Review
is made possible by:




NCT02134197 (Clinical Trial/ BAY1129980)

Study Title
Dose-escalation Study of BAY1129980 (NCT02134197)

Trial Description
The purpose of this study is to evaluate:

  • The side effects of BAY1129980 when given every 21 days different dose levels.
  • Determine the dose level of BAY1129980 that should be tested in future clinical research studies.
  • Measure how much BAY1129980 is in the blood at specific times after administration.
  • If treatment with BAY1129980 shows any effect on reducing the tumor growth.
  • If there are specific biomarkers that might be able to explain why some patients respond to treatment and others do not.
  • If treatment with BAY1129980 causes an immune response from the body against the drug (immunogenicity).

This trial is sponsored by Bayer®

Study Data

  • Condition: Neoplasms
  • Interventions:
    • Drugs used in this trial
      • BAY1129980
  • Phase: I
  • Estimated Enrollment: 60
  • Start: May 2014
  • Estimated Completion: December 2018
  • Last verified:September 2017
  • Last updated: September 2017

Study Schematic

Click here to Return to Drug map


Last Editorial review: September 2017
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.

Copyright © 2015-2017 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.


Share

Recommended Articles

Four Ways to Show Nonobviousness of ADC Inventions

05 October, 2018

When the first antibody-drug conjugate (ADC) was approved by the U.S. Food and Drug Administration (FDA) in 2000,[1] only a handful of patent applications claiming ADCs had been published.[2] As research cont...


Skip to toolbar